Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Sponsor
Beijing Haidian Hospital
Study ID
NCT05034133
Phase
PHASE2
Status
Unknown

Conditions

  • Limited Stage Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Durvalumab (IV 1000mg on day 1) with chemotherapy (Etoposide and Cisplatin) for 6 cycles

Study Details

This is a single arm Phase II study, in which 6 cycles of durvalumab with chemotherapy (Etoposide and Cisplatin) and durvalumab followed by Sequential radiotherapy for limited stage small cell lung cancer.

Key Dates

Start date
Sep 1, 2021
Status verified
Sep 2021
Primary completion
Aug 31, 2023
Completion
Aug 31, 2024

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study arm
    Patients with limited stage small cell lung cancer receive durvalumab with chemotherapy (Etoposide and Cisplatin) for receive 6 cycles, and then receive thoracic radiotherapy.

Primary Outcome Measure

Progression free survival [ Time Frame: Each 42 days up to intolerance the toxicity or PD (up to 24 months) ]

Central Contacts

Related Studies